Miltenyi, 170-076-191, MACS® GMP PepTivator® JCV VP1

Background information
The John Cunningham virus (JCV) is a widespread human polyomavirus with homology to BK polyomavirus (BKV). Primary JCV infection results in asymptomatic latent persistence of the virus in the gastrointestinal tract and the kidney. Immunodeficiency or immunosuppression allows virus reactivation, which can cause, e.g., a fatal progressive multifocal leukoencephalopathy. VP1 is the major capsid protein expressed late in the lytic cycle. It is described to induce T cell immunity.

Applications
The in vitro stimulation of JCV-specific CD4+ and CD8+ T cells with MACS® GMP PepTivator JCV VP1 causes the production of the effector cytokine IFN-gamma. This product has not yet been tested in conjunction with the CliniMACS Cytokine Capture System (IFN-gamma).

Quality statement
MACS GMP Products are manufactured and tested under a quality management system (ISO 13485) and are in compliance with relevant GMP guidelines. They are designed following the recommendations of USP <1043> on ancillary materials.

Disclaimer
MACS GMP Products are for ex vivo cell processing only, and are not intended for human in vivo applications. For regulatory status in the USA, please contact your local representative.

Overview
The MACS GMP PepTivator JCV VP1 is a peptide pool that consists mainly of 15-mer peptides with eleven amino-acids overlap. It has been developed for efficient in vitro stimulation and subsequent isolation of JCV VP1-specific CD4+ and CD8+ T cells.